ATE400264T1 - Methoden zur behandlung von nierenversagen - Google Patents

Methoden zur behandlung von nierenversagen

Info

Publication number
ATE400264T1
ATE400264T1 AT97948333T AT97948333T ATE400264T1 AT E400264 T1 ATE400264 T1 AT E400264T1 AT 97948333 T AT97948333 T AT 97948333T AT 97948333 T AT97948333 T AT 97948333T AT E400264 T1 ATE400264 T1 AT E400264T1
Authority
AT
Austria
Prior art keywords
patient
methods
ferric
accordance
kidney failure
Prior art date
Application number
AT97948333T
Other languages
English (en)
Inventor
Chen Hsing Hsu
Original Assignee
Chen Hsing Hsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26708838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE400264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Hsing Hsu filed Critical Chen Hsing Hsu
Application granted granted Critical
Publication of ATE400264T1 publication Critical patent/ATE400264T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97948333T 1996-12-16 1997-11-14 Methoden zur behandlung von nierenversagen ATE400264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3274596P 1996-12-16 1996-12-16
US08/794,328 US5753706A (en) 1996-12-16 1997-02-03 Methods for treating renal failure

Publications (1)

Publication Number Publication Date
ATE400264T1 true ATE400264T1 (de) 2008-07-15

Family

ID=26708838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948333T ATE400264T1 (de) 1996-12-16 1997-11-14 Methoden zur behandlung von nierenversagen

Country Status (12)

Country Link
US (1) US5753706A (de)
EP (1) EP0959878B1 (de)
JP (2) JP4173553B2 (de)
KR (1) KR100464504B1 (de)
AT (1) ATE400264T1 (de)
AU (1) AU723091B2 (de)
CA (1) CA2272711C (de)
DE (1) DE69738824D1 (de)
ES (1) ES2310417T3 (de)
IL (1) IL130041A (de)
NO (1) NO327148B1 (de)
WO (1) WO1998026776A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP2004503301A (ja) * 2000-06-15 2004-02-05 ガンブロ　ルンデイア　アクチーボラグ 透析においてカルシウムのプロファイルを作る方法および装置
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
WO2005012309A1 (fr) 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Bioisosteres cycliques issus d'un systeme purine et composition pharmaceutique a base desdits bioisosteres
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1945196A2 (de) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesiumhaltige polymere für hyperphosphatämie
EP3066923B1 (de) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Verfahren zur behandlung chronischer nierenkrankheiten
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
BRPI0816066A2 (pt) * 2007-08-31 2017-05-02 C B Fleet Company Incorporated método de prevenção de nefrocalcinose
EP2334292B1 (de) * 2008-10-17 2019-05-08 Fresenius Medical Care Holdings, Inc. Verfahren zur bestimmung einer phosphorbinder-dosis für einen dialysepatienten
EP2340821B1 (de) * 2008-10-27 2017-01-25 SBI Pharmaceuticals Co., Ltd. Mittel zur prophylaxe/linderung von erwachsenenkrankheiten mit 5-aminolevulinsäure, einem 5-aminolevulinsäure-derivat oder einem 5-aminolevulinsäure-salz oder 5-aminolevulinsäure-derivat als wirkstoff
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
AU2010300386B2 (en) * 2009-10-01 2014-03-20 Fresenius Medical Care Holdings, Inc. Method of calculating a phosphorus-protein ratio
EP2594277A4 (de) * 2010-07-07 2014-01-01 Japan Tobacco Inc Tablette mit eisencitrat
CA2824646C (en) * 2011-01-18 2020-07-14 Japan Tobacco Inc. Ferric citrate containing substantially no .beta.-oxidized iron hydroxide
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
WO2015110968A1 (en) 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (de) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmazeutische zusammensetzungen mit eisencitrat und verfahren zur herstellung davon
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
JP6206420B2 (ja) * 2015-01-13 2017-10-04 テクノサイエンス株式会社 クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法
JP2018526349A (ja) 2015-08-05 2018-09-13 ルピン・リミテッド 医薬品グレードのクエン酸第二鉄の調製のためのプロセス
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1131360B (de) * 1957-11-26 1962-06-14 Vitarine Company Inc Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten
DE3228231A1 (de) * 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
JPH08198760A (ja) * 1995-01-20 1996-08-06 Japan Organo Co Ltd 経口用リン酸イオン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure

Also Published As

Publication number Publication date
JP2007217429A (ja) 2007-08-30
IL130041A0 (en) 2000-02-29
NO992936L (no) 1999-08-13
KR100464504B1 (ko) 2004-12-31
IL130041A (en) 2005-08-31
AU723091B2 (en) 2000-08-17
KR20000069414A (ko) 2000-11-25
ES2310417T3 (es) 2009-01-01
US5753706A (en) 1998-05-19
CA2272711C (en) 2008-04-29
EP0959878A4 (de) 2002-03-27
AU5441998A (en) 1998-07-15
NO327148B1 (no) 2009-05-04
EP0959878A1 (de) 1999-12-01
WO1998026776A1 (en) 1998-06-25
NO992936D0 (no) 1999-06-16
JP2001506262A (ja) 2001-05-15
EP0959878B1 (de) 2008-07-09
DE69738824D1 (de) 2008-08-21
CA2272711A1 (en) 1998-06-25
JP4173553B2 (ja) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE400264T1 (de) Methoden zur behandlung von nierenversagen
Lockwood et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
EA199800399A1 (ru) Сульфатные конъюгаты урсодезоксихолевой кислоты и их применение в лечебных целях при воспалительных заболеваниях и других случаях
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
WO2003011225A3 (en) Calcium glutarate supplement and phosphorus binder
Tori et al. Urolithiasis in children with spinal cord injury
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
Hautmann et al. Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria
ATE198049T1 (de) Behandlung von magen- und darmgeschwüren mit morphogenen
Hanno et al. KAPOSI'S ARCOMA: WITH EXTENSIVE SILENT INTERNAL INVOLVEMENT
Lacher et al. Sweating treatment for chronic renal failure
Brunner et al. Chronic Mesenteric Arterial Insufficiency Caused by Vascular Neurofibromatosis.
Bliss Calciphylaxis: what nurses need to know.
NIENHUIS Clinical peritoneal dialysis
Rubin et al. A double blind trial of dipyridamole in CAPD
Lichtenberg et al. Tolbutamide-associated hyponatremia
Gasbarrini et al. Pirenzepine in the treatment of benign gastroduodenal diseases. A double-blind controlled clinical trial
RU2005487C1 (ru) Способ лечения бронхолегочных заболеваний
SU1454472A1 (ru) Способ лечени гнойно-фибринозного плеврита
RU2182003C2 (ru) Способ лечения нарушения энтерогепатической циркуляции желчи у больных с наружным дренированием желчных путей
Gibb et al. Survival in Whipple's disease
SU1153921A1 (ru) Способ лечени неспецифических эндобронхитов
Weisse Mercury Finally ‘Makes It’

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0959878

Country of ref document: EP